LYRA vs. ZYXI, NEPH, WOK, SURG, NMTC, RBOT, ECOR, MODD, PSTV, and TMDIF
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Zynex (ZYXI), Nephros (NEPH), WORK Medical Technology Group (WOK), SurgePays (SURG), NeuroOne Medical Technologies (NMTC), Vicarious Surgical (RBOT), electroCore (ECOR), Modular Medical (MODD), Plus Therapeutics (PSTV), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs. Its Competitors
Zynex (NASDAQ:ZYXI) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.
29.7% of Zynex shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Zynex has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
In the previous week, Lyra Therapeutics had 4 more articles in the media than Zynex. MarketBeat recorded 8 mentions for Lyra Therapeutics and 4 mentions for Zynex. Lyra Therapeutics' average media sentiment score of 1.06 beat Zynex's score of 0.48 indicating that Lyra Therapeutics is being referred to more favorably in the news media.
Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Zynex has a net margin of -19.79% compared to Lyra Therapeutics' net margin of -5,043.64%. Zynex's return on equity of -78.54% beat Lyra Therapeutics' return on equity.
Zynex currently has a consensus price target of $4.90, suggesting a potential upside of 195.18%. Lyra Therapeutics has a consensus price target of $100.00, suggesting a potential upside of 1,264.07%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Zynex.
Summary
Zynex beats Lyra Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access